Eton Pharmaceuticals Plans Phase 2 Mecasermin Trial for Pediatric Epileptic Spasms in Q1 2027
Bitget2026/11/02 11:50- Eton Pharmaceuticals launched ET-900 to evaluate mecasermin for infantile and epileptic spasms, targeting a new use for INCRELEX’s active ingredient.
- Licensed patent rights from Baylor College of Medicine underpin the program; Eton retains commercial rights, supporting its planned pediatric neurology expansion.
- An FDA investigational new drug application was submitted for an investigator-sponsored Phase 2 trial, with initial dosing targeted for first-quarter 2027.
- The University of Chicago-sponsored study will enroll up to 20 patients ages 2-18 with refractory epileptic spasms across three sites.
- Reported animal research showed reduced spasms, with some animals becoming spasm-free; the planned clinical trial will evaluate efficacy, safety and tolerability.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
